Viewing Study NCT05162066

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 4:12 PM
Ignite Modification Date: 2026-05-24 @ 7:07 PM
Study NCT ID: NCT05162066
Status: TERMINATED
Last Update Posted: 2024-05-02
First Post: 2021-11-26
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)
Sponsor: BioCryst Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Complement 3 Glomerulopathy View
None Immunoglobulin A Nephropathy View
None Membranous Nephropathy View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Complement 3 Glomerulopathy View
None Immunoglobulin A Nephropathy View
None BCX9930 View
None factor D inhibitor View
None oral therapy View
None Primary Membranous Nephropathy View